Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epivir (3TC) Clear all
Completed Phase 3 Interventional

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

NCT00035789
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 9, 2026, 4:13 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

NCT01338025
View directory record Official record
Conditions
HIV Disease
Interventions
HAART regimen, 3TC or FTC monotherapy
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
8 Years to 24 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

NCT01386970
View directory record Official record
Conditions
HIV
Interventions
zidovudine 300mg and lamivudine 150mg as Combivir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 9, 2026, 4:13 PM EDT
Active, not recruiting Phase 3 Interventional

Reducing Vertical Transmission of Hepatitis B in Africa

NCT04704024
View directory record Official record
Conditions
Hepatitis B Infection
Interventions
Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

NCT00053638
View directory record Official record
Conditions
HIV Infection
Interventions
efavirenz, tenofovir, abacavir/lamivudine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
58
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

NCT00000923
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

NCT00004578
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
10
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 9, 2026, 4:13 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Terminated Phase 3 Interventional Results available

Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone

NCT00376259
View directory record Official record
Conditions
Hepatitis B
Interventions
telbivudine, adefovir dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
San Diego, California • San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Switching From Epzicom to Truvada

NCT00724711
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 9, 2026, 4:13 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299
View directory record Official record
Conditions
HIV-1-Infection
Interventions
ISL/LEN, Antiretroviral Combinations
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

NCT00132652
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Lamivudine, Telbivudine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
San Diego, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

NCT02105987
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC, Ongoing cART regimen
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
87
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 9, 2026, 4:13 PM EDT
Not listed Phase 4 Interventional

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00005000
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 4:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

NCT01528865
View directory record Official record
Conditions
Lymphoma
Interventions
Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002407
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

NCT00004736
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Oct 9, 2026, 4:13 PM EDT
Completed No phase listed Observational

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

NCT06393387
View directory record Official record
Conditions
Hiv, HIV-1-infection, HIV Infections
Interventions
DTG/3TC versus BIC/F/TAF
Drug
Lead sponsor
Midway Specialty Care Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 9, 2026, 4:13 PM EDT